Trump administration cuts undocumented immigrants’ access to range of federally funded programs
HHS will limit immigrants' access to more federally funded programs, like health clinics and head start.
STAT+: Bionic knee developed by MIT researchers gives amputees a new world of motion
A bionic knee developed by Massachusetts Institute of Technology researchers is giving amputees a new world of motion.
STAT+: Academic groups finalize counterproposal to Trump’s research overhead cuts
Ten groups representing universities, medical centers, and others have wrapped up an alternative to the Trump administration's plan to cut billions of dollars in research overhead payments.
NIH grant cuts, FDA transparency questions, and biotech M&A
On this week's episode of "The Readout LOUD": a closer look at the NIH’s grant-cutting legal playbook, FDA transparency questions, and another big biotech acquisition.
FDA grants full approval to Moderna’s Covid vaccine for children but limits eligibility
Moderna’s Covid vaccine for children has been given full FDA approval, making it the first such shot for kids in the U.S. that will no longer be administered under an…
STAT+: FDA won’t pay 2024 bonuses to workers who are getting laid off
This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and medicine.
STAT+: FDA publishes rejection letters sent to drugmakers, with a big caveat
The FDA published more than 200 letters that it sent to companies when it rejected their medicines, but the letters came with a caveat.
STAT+: Brawl over Eylea gets biosimilar industry’s attention
Plus other biotech news brought to you by The Readout newsletter.
STAT+: Pharmalittle: We’re reading about Regeneron’s patent maneuvers, FDA rejection letters, and lots more
A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to thwart competition
STAT+: Renasant Bio, an underdog in the race to develop kidney disease therapies, raises $54.5 million
With investors and drugmakers increasingly eyeing the kidney disease space, a new company hopes to shed its underdog status to create treatments for a hard-to-treat condition.